Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.

Authors:
Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H and 3 more

Journal:
Clin Exp Allergy

Publication Year: 2020

DOI:
10.1111/cea.13566

PMCID:
PMC7065003

PMID:
31925825

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Exp Allergy

Abbreviation: Clin Exp Allergy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Anaphylaxis in Brazil between 2011 and 2019.
Tanno LK; Molinari N; Annesi-Maesano I and 2 more (2022) - Transparency Score: 3/6
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with na…
Eide JG; Wu J; Stevens WW and 16 more (2022) - Transparency Score: 3/6
Association between allergic sensitization and intestinal parasite infection in schoolchildren in G…
Brandt O; Wegenstein B; Müller I and 12 more (2022) - Transparency Score: 3/6
Burden of allergic disease among ethnic minority groups in high-income countries.
Jones CJ; Paudyal P; West RM and 5 more (2022) - Transparency Score: 2/6
Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctiv…
de Blay F; Gherasim A; Domis N and 2 more (2022) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST M. van den Elzen received reimbursements to attend symposia and speaker's fees from Novartis Pharma B.V. to the institution. AC Knulst received funds for research and healthcare innovation from Novartis Pharma B.V. to the institution and was involved in the advisory board of Novartis Pharma B.V. H. Röckmann received speaker's fees, and funds for research from Novartis Pharma B.V. to the institution. Remaining authors None declared."

Evidence found in paper:

"Funding information"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025